Second-generation antipsychotics in the treatment of major depressive disorder: current evidence
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Major depressive disorder (MDD) is a chronic and recurrent mental condition leading to huge impacts on direct and indirect personal and public medical costs. To overcome such a serious mental disorder, we currently have a number of different classes of antidepressants, such as selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, noradrenergic and specific serotonin receptor antagonists, dopamine and norepinephrine reuptake inhibitors, along with newly introduced antidepressants (e.g., vilazodone and agomelatine). However, a number of well-controlled clinical trials, meta-analyses and practical clinical studies have found that only a third of such MDD patients remit following adequate antidepressant treatment, while most MDD patients suffer from significant core depressive or residual symptoms during their clinical course. There have been some treatment approaches to overcome such a shortage of antidepressant efficacy, such as augmentation of psychotropics other than antidepressants, switching to a different antidepressant and combinations of different antidepressants. Among these different second treatment options, augmentation treatment has some favorable points compared with the combination and switching option (e.g., maintaining previous antidepressant partial response, synergistic effect between different pharmacological profile and no need to wash out previous antidepressants). Recently, second-generation antipsychotics (SGAs), olanzapine plus fluoxetine, quetiapine extended release and aripiprazole have clearly demonstrated efficacy in the treatment of MDD patients through a number of small-scale, open-label studies or randomized, placebo-controlled clinical trials. Eventually, in November 2007, aripiprazole was the first approved by the US FDA as an adjunctive treatment to antidepressants for treating MDD, followed by the approval of quetiapine and olanzapine plus fluoxetine at 2009. This comprehensive review provides an overview of the clinical trial data of SGAs for treating MDD and clinical issues raised in the use of SGA therapy in patients with MDD in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797
Residual symptoms after partial remission: an important outcome in depression
Paykel, E. S., Ramana, R., Cooper, Z., Hayhurst, H., Kerr, J., & Barocka, A. (1995) · Psychological Medicine · doi:10.1017/s0033291700033146 · Cited by 791
Marcus, R. N., McQuade, R. D., Carson, W. H., Hennicken, D., Fava, M., Simon, J. S., Trivedi, M. H., Thase, M. E., & Berman, R. M. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31816774f9 · Cited by 518
Nierenberg, A. A., Husain, M. M., Trivedi, M. H., Fava, M., Warden, D., Wisniewski, S. R., Miyahara, S., & Rush, A. J. (2010) · Psychological Medicine · doi:10.1017/s0033291709006011 · Cited by 458
Lam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431
Berlim, M. T., & Turecki, G. (2007) · The Canadian Journal of Psychiatry · doi:10.1177/070674370705200108 · Cited by 412
Berman, R. M., Fava, M., Thase, M. E., Trivedi, M. H., Swanink, R., McQuade, R. D., Carson, W. H., Adson, D., Taylor, L., Hazel, J., et al. (2009) · CNS Spectrums · doi:10.1017/s1092852900020216 · Cited by 260
The 5-HT7 receptor and disorders of the nervous system: an overview
Hedlund, P. B. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1626-0 · Cited by 239
Thase, M. E., Corya, S. A., Osuntokun, O., Case, M., Henley, D. B., Sanger, T. M., Watson, S. B., & Dubé, S. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0207 · Cited by 228
Cited by
Durgam, S., Earley, W., Guo, H., Li, D., Németh, G., Laszlovszky, I., Fava, M., & Montgomery, S. A. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10070 · Cited by 125
A review of current evidence for acetyl-l-carnitine in the treatment of depression
Wang, S.-M., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.02.005 · Cited by 110
“…naturalistic origin agents have been tried to test their therapeutic effects to augment ongoing antidepressants, producing diverse clinical results (Han et al., 2012, 2013; Iosifescu et al., 2005; Khajavi et al., 2012; Pae, 2013; Pae, in press; Pae and Forbes, 2011; Pae et al., 2008; Papakostas…”
BackgroundSelf-citationBrubaker, M., Kapadia, S., Maletic, V., Chambers, J., Watling, C., & Citrome, L. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s501207 · Cited by 7
Metadata
- Authors
- Han, C., Wang, S.-M., Kato, M., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2013-07
- Volume
- 13
- Issue
- 7
- Pages
- 851-870
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2074874853
- Cited by
- 92
- References
- 18
- FWCI
- 6.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. https://app.cochat.ai/papers/10.1586/14737175.2013.811901
- The paper
- Han, C., Wang, S.-M., Kato, M., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2013). Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.2013.811901
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.